A Survey of Isosteric Amide Replacements in a Series of Extended, Hydroxamate-containing, Selective MMP-13 Inhibitors Thomas E. Barta Abstract: Seeking compounds preferentially potent and selective for MMP-13, we recently reported on a series of hydroxamic acids with a flexible benzamide tail groups. 1 In this Letter, we replace the amide moiety with non-hydrolyzable heterocycles in an effort to improve half-life. We identify a hydroxamate tetrazole 4e that spares MMP-1 and -14, shows >400 fold selectivity vs. MMP-8 and >600 fold selectivity vs. MMP-2, and has a 4.8 h half-life in rats.
Matrix Metalloproteinases (MMPs) are a family of about 27 zinc-dependent enzymes responsible for the turnover of collagen in connective tissue. There are a variety of disease states where degradation of collagen contributes to the pathology, specifically, in osteo-and rheumatoid arthritis; in tumor angiogenesis and metastasis; in post-MI cardiovascular remodeling. In the previous Letter, 1a we note that joint-stiffening, "musculoskeletal syndrome" (MSS), upon prolonged dosing with MMP inhibitors (MMPi's) has prevented approval of an MMPi. Efforts have been made to spare MMP isoforms that are thought to contribute to MSS, specifically, MMP-1 and -14 (MT1-MMP) (SD-2590, fig. 1 ), 1b but a more focused approach toward realizing efficacious MMP inhibitors with reduced side effects should be to focus on optimizing a single MMP isoform that confers the most therapeutic benefit, reducing the probability of off-target protease binding. MMP-13, upregulated in osteoarthritic joints and in cancer, is an attractive isoform to target, and structural studies show that -13 differs from other MMP's deep in the S1' pocket, suggesting that lengthier inhibitors may confer selectivity.
With this in mind, we elaborated a series of rigid piperidino-ketones (compound 2, Figure 1 ) with lengthier P1' subunits and, with optimization, we were able to achieve significant selectivity for MMP-13 vs. other MMP isoforms. 2 Conceptually dissecting the piperidine ring in compound 2, we also wanted to explore acyclic-chain analogs such as amide 3 (Figure 1) . 1 While excellent MMP-13 selectivity ( Table 1 ) was achieved with a number of amides related to compound 3, the amides displayed short half-life in rats, presumably due to hydrolytic cleavage of the amide bond. In an effort to prepare compounds with suitable selectivity and PK, we incorporated the SAR findings from the acyclic amide series into a small series of compounds where the amide is replaced by isosteric heterocycles. This Letter summarizes that effort.
Among the isosteres we wanted to consider were tetrazoles. Entry into this series began by alkylating the requisite 5-phenyl-1H-tetrazoles (e.g. 5, scheme 1) using O-tetrahydropyranyl-3chloropropanol. Alkylation afforded predominantly the desired 2-isomers for 5-[4methoxyphenyl]-and 5-[4-trifluoromethoxyphenyl]-tetrazole, and the products were purified by chromatography. The THP protecting group could be removed with acid and the product alcohol (e.g. 6) reacted with the known aryl fluoride 7. 1 The t-butyl ester 8 was cleaved and the resulting acid reacted with O-tetrahydropyranyl hydroxylamine in the presence of EDC. Removal of the THP gave the desired hydroxamic acids 4b. In the case of 5-[4-methyl-2-pyridyl]-tetrazole, alkylation gave a 3:2 mixture, still favoring the 2-position. The poor selectivity in the alkylation step afforded us the opportunity to isolate meaningful quantities of both 2-and 1-isomers and to carry the isomers individually on to final product (4d and 4e, table 1).
Oxadiazoles (e.g 4f, Table 1 ) were prepared by combining the known acid 9 1 and 4-(trifluoromethoxy)benzamidoxime in the presence of EDC, then heating the coupled product to close the ring. After condensation of the oxadiazole, the t-butyl ester (10, Scheme 2) is carried on to the hydroxamic acid employing the same transformations used for the tetrazoles.
From Table 1 , we see that replacing the amide in 3 ( Table 1) with various aryl heterocycle combinations: tetrazoles (4a-e); oxadiazoles (4f,g); and imidazoles (4h,i) continues to demonstrate high levels of selectivity for MMP-13 vs. MMP-1, -2, -7, -8, -9, and -14. Selectivity vs. MMP-3 is lowered. Unexpectedly, we see that the 1,5-isomer of the pyridyl analog (4e) has a selectivity profile very similar to its 2,5-substituted isomer (4d). These results inspired us to make some similarly disposed imidazoles (4j). We also made an isomeric 1,5-substituted tetrazole, where the tetrazole carbon connects to the acyclic chain, by a chemospecific method 5 (scheme 2) not involving N-alkylation (4j).
The crystal structure of tetrazole 4c was determined at 1.9Å resolution (Figure 2) . 6 The selectivity in this series derives from the depth and flexibility of the MMP-13 S1' pocket, which is distinct from other MMP family members such as MMP-1 and MMP-2, with shorter pockets. The tetrazole group forms a single direct hydrogen bond to the protein backbone at Thr245 (3.0Å); the remainder of the side chain interactions with the protein are van der Waals contacts. The S1' pocket of MMP-13 readily morphs to interact with inhibitors of various sizes and shapes, as we see in the case of tetrazoles 4d and 4e. We were able to achieve >10 3 selectivity vs. most other MMP family members with 4c, but even more specific compounds may be possible with this or other scaffolds.
We were able to improve on the 0.59 h half-life we measured for the lead amide compound 3; from Table 1 , we see heterocyclic compounds with half-lifes ranging from 1.4 to 4.8 h, some compounds having good BA (e.g. tetrazole 4c, 26%; and oxadiazole 4f, 28%) and achieving encouraging Cmax. Based on our data, we believe selected heterocyclic analogs in this Letter would be promising drug candidates for the treatment of arthritis, cancer, and post-MI left ventricular hypertrophy (CHF). 1 eq), NMP, rt; then 2-(3-chloropropoxy)tetrahydro-2Hpyran (1.1 eq) r.t. to 70°C (45%) (b) AcCl (3.8 eq), MeOH, rt (94%) (c) 6 (1.05 eq), NaH (1.1 eq), NMP, 55°C, 1h (70%) (d) NaOH (50% aq, 10 eq), THF, EtOH, rt to 60°C, then acidify w/ HCl, conc., azeotrope CH 3 CN (e) triethylamine (XS), HOBT, THPONH 2 (1.5 eq based on 7a), EDC (1.5), DMF, 40 h (65%) (f) AcCl (4 eq), MeOH, trit. ether (74%) 2.9 21900 (20) Figure 2 . Structure of MMP-13 with compound 4c bound at the catalytic site. The inhibitor binds deeply within the S1' pocket of the active site and causes a conformational change opening the loop to accommodate the compound. The hydroxamate moiety chelates the zinc ion at two positions, and Glu223 forms a hydrogen bond to the hydroxamate. Similarly, the hydroxamate nitrogen atom forms a hydrogen bond to the protein backbone, as does one of the sulfone oxygen atoms. A single hydrogen bond is formed between the tetrazole and the protein backbone. A HEPES buffer molecule bound adjacent to the inhibitor in two of the four protein molecules in the crystal, and an array of solvent atoms form an auxiliary van der Waals surface between the inhibitor and the protein. 6 
